February 24th, 2012
A few weeks ago, I represented Janssen Therapeutics, Division of Janssen Products, LP, at a National HIV/AIDS Strategy (NHAS) implementation meeting convened by the U.S. Department of Health and Human Services.
We are very excited to be taking an active role in contributing to the implementation of this first-ever National HIV/AIDS Strategy. In fact, this meeting I attended was the third NHAS implementation meeting our company has attended and at each of these meetings, we’ve been joined by representatives of other corporations, foundations, HIV community groups and other stakeholders who came together to discuss how best to achieve the goals of the NHAS.
Released by the White House on July 13, 2010, the vision of the NHAS is clear: The United States will become a place where new HIV infections are rare and when they do occur, every person regardless of age, gender, race/ethnicity, sexual orientation, gender identity or socio-economic circumstance, will have unfettered access to high quality, life-extending care, free from stigma and discrimination.
To achieve this vision, the NHAS has target goals through 2015 in three areas:
• Reduce HIV incidence
• Increase access to care and improve health outcomes for people living with HIV
• Reduce HIV-related health disparities
Participating in the ongoing dialogue is just one of the steps Janssen Therapeutics is taking to support the NHAS. For example, we have earmarked a significant portion of our giving to fund the Access to Care Initiative, which supports innovative technologies and initiatives that enable access to care in underserved communities. Specifically, this Social Innovation Fund program is funding 10 collaborations of nonprofits, researchers and others with a goal to connect at least 3,500 low income people living with HIV to high quality health care and supportive services.